Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
BMIQ9
MCID: BDY005
MIFTS: 48

Body Mass Index Quantitative Trait Locus 9 (BMIQ9)

Categories: Bone diseases, Genetic diseases, Metabolic diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 9

About this section

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 9:

Name: Body Mass Index Quantitative Trait Locus 9 56 29 6 39
Obesity, Severe, Susceptibility to, Bmiq9 56 13
Obesity 56 71
Obesity, Susceptibility to 56
Obesity, Severe Bmiq9 56
Bmiq9 56

Characteristics:

OMIM:

56
Inheritance:
broad locus on 20q


Classifications:

MalaCards categories:
Global: Genetic diseases Metabolic diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 56 602025
MedGen 41 C2677162
SNOMED-CT via HPO 68 414915002 414916001
UMLS 71 C0028754
Sources

Summaries for Body Mass Index Quantitative Trait Locus 9

About this section
MalaCards based summary : Body Mass Index Quantitative Trait Locus 9, also known as obesity, severe, susceptibility to, bmiq9, is related to body mass index quantitative trait locus 11 and obesity, early-onset, with adrenal insufficiency and red hair, and has symptoms including symptoms, high weight and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 9 is MC3R (Melanocortin 3 Receptor). The drugs Oseltamivir and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and breast, and related phenotype is obesity.

More information from OMIM: 602025
Sources

Related Diseases for Body Mass Index Quantitative Trait Locus 9

About this section

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 9 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2052)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 11 12.7
2 obesity, early-onset, with adrenal insufficiency and red hair 12.7
3 morbid obesity and spermatogenic failure 12.7
4 leptin deficiency or dysfunction 12.6
5 genetic obesity 12.6
6 obesity-hypoventilation syndrome 12.6
7 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 12.5
8 obesity, hyperphagia, and developmental delay 12.5
9 abdominal obesity-metabolic syndrome 1 12.5
10 spastic paraplegia, intellectual disability, nystagmus, and obesity 12.5
11 retinal dystrophy and obesity 12.5
12 abdominal obesity-metabolic syndrome 3 12.5
13 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 12.5
14 hypothalamic obesity 12.5
15 hydrocephalus obesity hypogonadism 12.4
16 x-linked intellectual disability - short stature - obesity 12.4
17 body mass index quantitative trait locus 19 12.4
18 leptin receptor deficiency 12.3
19 body mass index quantitative trait locus 20 12.3
20 abdominal obesity-metabolic syndrome quantitative trait locus 2 12.3
21 aniridia - ptosis - intellectual disability - familial obesity 12.3
22 obesity due to melanocortin 4 receptor deficiency 12.3
23 abdominal obesity-metabolic syndrome 4 12.3
24 rapid-onset childhood obesity-hypothalamic dysfunction-hypoventilation-autonomic dysregulation syndrome 12.3
25 coloboma-obesity-hypogenitalism-mental retardation syndrome 12.2
26 short stature-obesity syndrome 12.2
27 mental retardation, obesity, mandibular prognathism, and eye and skin anomalies 12.2
28 prolactin deficiency with obesity and enlarged testes 12.2
29 cohen syndrome 12.2
30 obesity due to congenital leptin resistance 12.2
31 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 12.2
32 obesity due to sim1 deficiency 12.2
33 wilson-turner x-linked mental retardation syndrome 12.2
34 syndromic obesity 12.2
35 body mass index quantitative trait locus 12 12.2
36 body mass index quantitative trait locus 4 12.2
37 body mass index quantitative trait locus 14 12.2
38 body mass index quantitative trait locus 8 12.2
39 body mass index quantitative trait locus 7 12.2
40 body mass index quantitative trait locus 18 12.2
41 midface hypoplasia, obesity, developmental delay, and neonatal hypotonia 12.2
42 mehmo syndrome 12.1
43 body mass index quantitative trait locus 10 12.1
44 proprotein convertase 1/3 deficiency 12.1
45 genetic non-syndromic obesity 12.1
46 momo syndrome 12.1
47 chops syndrome 12.1
48 genetic overgrowth/obesity syndrome 12.0
49 overgrowth/obesity syndrome 12.0
50 x-linked intellectual disability-hypogonadism-ichthyosis-obesity-short stature syndrome 12.0

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 9:



Diseases related to Body Mass Index Quantitative Trait Locus 9
Sources

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 9

About this section

Human phenotypes related to Body Mass Index Quantitative Trait Locus 9:

31
# Description HPO Frequency HPO Source Accession
1 obesity 31 HP:0001513

Symptoms via clinical synopsis from OMIM:

56
Growth:
body fat content

Lab:
fasting insulin levels

Clinical features from OMIM:

602025

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 9:


symptoms, high weight, obesity, metabolically benign, monogenic obesity
Sources

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 9

About this section

Drugs for Body Mass Index Quantitative Trait Locus 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
2
Citalopram Approved Phase 4 59729-33-8 2771
3
Enalaprilat Approved Phase 4 76420-72-9 6917719
4
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
5
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
6
Vancomycin Approved Phase 4 1404-90-6 441141 14969
7
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
8
Lixisenatide Approved Phase 4 320367-13-3
9
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
10
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
11
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
12
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
13
Ticagrelor Approved Phase 4 274693-27-5 9871419
14
Tolnaftate Approved, Investigational, Vet_approved Phase 4 2398-96-1 5510
15
Dapsone Approved, Investigational Phase 4 80-08-0 2955
16
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
17
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
18
Acetaminophen Approved Phase 4 103-90-2 1983
19
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
20
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
21
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
22
Adenosine Approved, Investigational Phase 4 58-61-7 60961
23
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
24
Metronidazole Approved Phase 4 443-48-1 4173
25
Cisplatin Approved Phase 4 15663-27-1 84093 441203 2767
26
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
27
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
28
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
29
Losartan Approved Phase 4 114798-26-4 3961
30
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
31
Norepinephrine Approved Phase 4 51-41-2 439260
32
Enoxaparin Approved Phase 4 9005-49-6 772
33
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
34
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
35
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
36
Ibuprofen Approved Phase 4 15687-27-1 3672
37
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
38
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
39
Infliximab Approved Phase 4 170277-31-3
40
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
41
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
42
Racepinephrine Approved Phase 4 329-65-7 838
43
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
44
Nadroparin Approved, Investigational Phase 4
45
Tigecycline Approved Phase 4 220620-09-7 5282044
46
Memantine Approved, Investigational Phase 4 19982-08-2 4054
47
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
48
Lactulose Approved Phase 4 4618-18-2 11333
49
Ethambutol Approved Phase 4 74-55-5 3279 14052
50
Ziprasidone Approved Phase 4 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
2 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Unknown status NCT02952963 Phase 4 Chenodeoxycholic Acid;Colesevelam
3 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
4 The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
5 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
6 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
7 Effects of Chenodeoxycholic Acid and Colesevelam on GLP-1 Secretion, During a Meal, After Roux-en-Y Gastric Bypass Unknown status NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
8 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
9 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
10 A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity. Unknown status NCT01864187 Phase 4 Dexmedetomidine
11 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
12 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
13 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
14 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
15 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
16 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity: a Prospective,Controlled, Randomized, Multicentrique Study. Unknown status NCT01550601 Phase 4
17 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
18 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
19 Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region Unknown status NCT01881373 Phase 4
20 Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery. Unknown status NCT02295150 Phase 4 Nadroparin
21 Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity) Unknown status NCT02055014 Phase 4 Liraglutide
22 Beijing Chao-yang Hospital, Capital Medical University Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
23 Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade Unknown status NCT02118844 Phase 4 rocuronium
24 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
25 Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities Unknown status NCT02050477 Phase 4
26 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
27 Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome Unknown status NCT03325023 Phase 4
28 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
29 Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
30 International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
31 Influence of Erythromycin on ad Libitum Food Intake and the Evaluation of Motilin in Food Timing in Healthy Volunteers and Patients Unknown status NCT03024879 Phase 4 Erythromycin;Saline
32 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
33 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
34 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone（BLOOD STUDY） Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
35 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Unknown status NCT02959853 Phase 4 Anastrazole
36 Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
37 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Unknown status NCT02374632 Phase 4
38 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
39 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
40 What is the Effects of Prokinetic Drug on the Blood Glucose in Type 2 Diabetes Patients: Mosapride Comparing Placebo Unknown status NCT02606617 Phase 4 Mosapride;Placebo
41 Efficacy of Vitamin D Supplementation in Obese Children Unknown status NCT02956408 Phase 4
42 The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men Unknown status NCT03012113 Phase 4 Mirabegron;Placebo Oral Capsule
43 BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery Unknown status NCT03341429 Phase 4 Liraglutide Pen Injector [Saxenda];Placebo
44 Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults Unknown status NCT02524184 Phase 4 sildenafil;placebo
45 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
46 Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men Unknown status NCT02097680 Phase 4 Letrozole;Placebo
47 Determining the Minimal Effective Volume (MEAV95) for Interscalene Brachial Plexus Block for Surgical Anesthesia Unknown status NCT01703130 Phase 4
48 The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance Unknown status NCT02502344 Phase 4 Metformin
49 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
50 Changes in Central Aortic Pressure, Endothelial Function and Biomarkers in African Americans With Cardiometabolic Syndrome: Comparison of Amlodipine/Olmesartan Versus Hydrochlorothiazide/Losartan Unknown status NCT01271374 Phase 4 amlodipine and olmesartan;losartan and HCTZ

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 9

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Benzphetamine
Benzphetamine hydrochloride
Dexfenfluramine
Dexfenfluramine Hydrochloride
Diethylpropion
Diethylpropion Hydrochloride
Fenfluramine
Fenfluramine Hydrochloride
lorcaserin
lorcaserin hydrochloride
Mazindol
Methamphetamine
orlistat
phendimetrazine
PHENDIMETRAZINE HYDROCHLORIDE
phendimetrazine tartrate
Phenmetrazine
Phenmetrazine Hydrochloride
Phentermine
Phentermine Hydrochloride
PHENTERMINE RESIN
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
sibutramine
SIBUTRAMINE HYDROCHLORIDE
Sources

Genetic Tests for Body Mass Index Quantitative Trait Locus 9

About this section

Genetic tests related to Body Mass Index Quantitative Trait Locus 9:

# Genetic test Affiliating Genes
1 Body Mass Index Quantitative Trait Locus 9 29 MC3R
Sources

Anatomical Context for Body Mass Index Quantitative Trait Locus 9

About this section

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 9:

40
Liver, Heart, Breast, Brain, Testes, Kidney, Bone
Sources

Publications for Body Mass Index Quantitative Trait Locus 9

About this section

Articles related to Body Mass Index Quantitative Trait Locus 9:

(show top 50) (show all 30011)
# Title Authors PMID Year
1
Rare melanocortin-3 receptor mutations with in vitro functional consequences are associated with human obesity. 56 6
21047972 2011
2
Sporadic mutations in melanocortin receptor 3 in morbid obese individuals. 56 6
18231126 2008
3
Functional characterization of melanocortin-3 receptor variants identify a loss-of-function mutation involving an amino acid critical for G protein-coupled receptor activation. 56 6
15292330 2004
4
A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. 56 6
11889220 2002
5
Co-occurrence of two partially inactivating polymorphisms of MC3R is associated with pediatric-onset obesity. 61 56
16123355 2005
6
Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. 56
19091795 2009
7
Inactivation and intracellular retention of the human I183N mutated melanocortin 3 receptor associated with obesity. 6
15276649 2004
8
Interacting genetic loci on chromosomes 20 and 10 influence extreme human obesity. 56
12478478 2003
9
Linkage of body mass index to chromosome 20 in Utah pedigrees. 56
11702208 2001
10
Genome scan for human obesity and linkage to markers in 20q13. 56
9915959 1999
11
Identification of an obesity quantitative trait locus on mouse chromosome 2 and evidence of linkage to body fat and insulin on the human homologous region 20q. 56
9276742 1997
12
Methods for the study of histocompatibility genes. 56
18893744 1948
13
Associations between obesity and neighborhood socioeconomic status: Variations by gender and family income status. 61
31890849 2020
14
Adolescent stress: A predictor of dieting behaviors in youth with overweight/obesity. 61
31870936 2020
15
Obesity in midlife: lifestyle and dietary strategies. 61
31576760 2020
16
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. 61
31733195 2020
17
The relationship between cortisol and IGF-I influences metabolic alteration in pediatric overweight and obesity. 61
31863690 2020
18
Chemokines in human obesity. 61
31865065 2020
19
Dietary management of blood glucose in medical critically ill patients with overweight/obesity. 61
32004236 2020
20
Obesity-Induced Regulator of Calcineurin 1 Overexpression Leads to β-Cell Failure Through Mitophagy Pathway Inhibition. 61
31822118 2020
21
Assessing the acceptability of an adapted preschool obesity prevention programme: ToyBox-Scotland. 61
31856335 2020
22
Guidelines for the management of pregnant women with obesity: A systematic review. 61
31943650 2020
23
Obesity and dental caries in early childhood: A systematic review and meta-analyses. 61
31721413 2020
24
A scoping review on economic globalization in relation to the obesity epidemic. 61
31724312 2020
25
Depression subtypes and obesity in adults: A systematic review and meta-analysis. 61
31724325 2020
26
The effect of interaction between parity, gestational diabetes, and pregravid obesity on the incidence of preeclampsia. 61
30081684 2020
27
Words with weight: The construction of obesity in eating disorders research. 61
29992834 2020
28
Obesity in youth and adults with intellectual disability in Europe and Eurasia. 61
31482623 2020
29
Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity. 61
31845423 2020
30
Re: Association between enuresis and obesity in children with primary monosymptomatic nocturnal enuresis. 61
32022532 2020
31
Pediatric obesity treatment, self-esteem, and body image: A systematic review with meta-analysis. 61
32020780 2020
32
Associations of nitric oxide with obesity and psychological traits among children and adolescents in Taiwan. 61
31786830 2020
33
Metabolically healthy general and abdominal obesity are associated with increased risk of hypertension. 61
31791429 2020
34
The Role of Obesity in Iatrogenic Encephaloceles of the Temporal Bone. 61
31851068 2020
35
Age of obesity onset, cumulative obesity exposure over early adulthood and risk of type 2 diabetes. 61
31858184 2020
36
Ripple Effects of the Communities Preventing Childhood Obesity Project. 61
30117342 2020
37
More precise prevalence of overweight and obesity. 61
31762168 2020
38
Obesity: A preventable, treatable, but relapsing disease. 61
31864969 2020
39
Diabetes Mellitus, Obesity, and the Placenta. 61
32008672 2020
40
Leptin, obesity, and response to ketamine. 61
31672525 2020
41
Steroid Metabolomic Signature of Insulin Resistance in Childhood Obesity. 61
31727688 2020
42
Management of obesity in adolescents with polycystic ovary syndrome. 61
31893931 2020
43
White adipose tissue mitochondrial metabolism in health and in obesity. 61
31777187 2020
44
Medical and surgical management of obesity and diabetes: what's new? 61
31850536 2020
45
Longitudinal associations of toothbrushing with obesity and hyperglycemia. 61
32009102 2020
46
Comments on: Obesity associated with a novel mitochondrial tRNACys m.5802A>G mutation. 61
32010935 2020
47
Improving obesity and blood pressure. 61
31649313 2020
48
Calanus oil in the treatment of obesity-related low-grade inflammation, insulin resistance, and atherosclerosis. 61
31853565 2020
49
From Nissen Fundoplication to Roux-en-Y Gastric Bypass to Treat Both GERD and Morbid Obesity. 61
31768866 2020
50
Osteoporosis and osteoarthritis are two sides of the same coin paid for obesity. 61
31655472 2020
Sources

Variations for Body Mass Index Quantitative Trait Locus 9

About this section

ClinVar genetic disease variations for Body Mass Index Quantitative Trait Locus 9:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MC3R NM_019888.3(MC3R):c.437T>A (p.Ile146Asn)SNV risk factor 14339 rs74315393 20:54824336-54824336 20:56249280-56249280
2 MC3R NM_019888.3(MC3R):c.893T>G (p.Ile298Ser)SNV risk factor 14340 rs121913556 20:54824792-54824792 20:56249736-56249736
Sources

Expression for Body Mass Index Quantitative Trait Locus 9

About this section
Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 9.
Sources

Pathways for Body Mass Index Quantitative Trait Locus 9

About this section
Sources

GO Terms for Body Mass Index Quantitative Trait Locus 9

About this section
Sources

Sources for Body Mass Index Quantitative Trait Locus 9

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....